# AML18 (NCT02272478)

> Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02272478
- Phase: PHASE2, PHASE3
- Status: UNKNOWN
- Sponsor: Cardiff University
- Conditions: Acute Myeloid Leukaemia; Myelodysplastic Syndrome
- Interventions: Arm A Mylotarg plus DA Versus CPX-351; Arm B Vosaroxin and Decitabine; Arm D Small molecule or Not; Arm C DA V FLAG-Ida V DAC; Arm E CPX-351 (200 V 300); Arm F DA V IDAC
- Enrollment: 1600
- Primary outcome: Overall survival
- Primary outcome: Complete remission (CR + CRi) achievement and reasons for failure (for induction questions)
- Primary outcome: Duration of remission, relapse rates and deaths in first CR
- Primary outcome: Toxicity, both haematological and non-haematological
- Primary outcome: Supportive care requirements (and other aspects of health economics)

## Commentary we found

- Podcasts: 6
- YouTube: 4
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aml18-nct02272478

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02272478", "email": "<work email>"}; the inbox owner confirms by the emailed link.